Hoth Therapeutics, Inc. announced the appointment of Stefanie Johns, Ph.D., to the position of Chief Scientific Officer, effective as of September 8, 2020. In her role, Dr. Johns will further advance Hoth's pipeline through both preclinical and clinical stages. Stefanie Johns has worked in the biopharmaceutical and medical device industries for more than eight years, and has experience spanning drug, biologic, medical device, and in vitro diagnostic device products in US and global markets. Since January 2020, Dr. Johns has served as Director, Regulatory Affairs of Enable Injections, Inc., and from January 2019 until January 2020, she served as Associate Director, Regulatory Affairs of Enable Injections, Inc. From December 2018 until August 2018, Dr. Johns served as Manager, Regulatory Strategy of Camargo Pharmaceutical Services, LLC (Camargo) and from July 2016 until August 2018, she served as Scientific Regulator Specialist of Camargo. From June 2013 through June 2016, Dr. Johns served as Regulatory Affairs and Design Assurance Associate of Meridian Bioscience Inc. In addition, Dr. Johns previously served as Program Manager, Xavier Health Initiatives for Xavier University and a Graduate Research Assistant for the University of Cincinnati. Since March 2019, Dr. Johns has served on the company’s Scientific Advisory Board.